Paloma Vela

Paloma Vela

Auto-generated profile, based on publicly available information

Paloma Vela

Department of Rheumatology Hospital General Universitario de Alicante Alicante Spain

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 1999 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
EPEliseo Pascual
Eliseo Pascual
EBEnrique Batlle-Gualda
Enrique Batlle-Gualda
AMAgustín Martínez
Agustín Martínez
JRJosé Rosas
José Rosas
PVPaloma Vela
Paloma Vela
The diagnosis of gout in the intercritical phase can be difficult. To determine whether synovial fluid analysis allows the diagnosis of intercritical gout. Cross-sectional study. Outpatient rheumatology clinics. 101 patients with gout. Arthrocentesis of 80 knees and 21 first metatarsophalangeal joints (each joint from a different patient) that had been inflamed but were currently asymptomatic. Frequency with which arthrocentesis yielded synovial fluid; presence of monosodium urate crystals in the synovial fluid sample; and, for synovial fluid with crystals, the number of microscope fields that had to be scanned before crystals were found. Synovial fluid was obtained from 91 of 101 joints. The fluid from all 43 patients not receiving hypouricemic agents contained monosodium urate crystals. These crystals were found in the synovial fluid of only 34 of 48 patients receiving hypouricemic agents. In 90% of the synovial fluid samples that contained crystals, crystals were seen in the first five microscope fields examined. Arthrocentesis of asymptomatic knees and first metatarsophalangeal joints and synovial fluid analysis are simple procedures that facilitate the diagnosis of gout during intercritical periods.

30 May 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
AJAntonio Julià
Antonio Julià
FLFrancisco Javier López-Longo
Francisco Javier López-Longo
JVJosé Javier Pérez Venegas
José Javier Pérez Venegas
SBSilvia Bonàs-Guarch
Silvia Bonàs-Guarch
ÀOÀlex Olivé
Àlex Olivé
AFAntonio Fernandez-Nebro
Antonio Fernandez-Nebro
Systemic lupus erythematosus (SLE) is a common systemic autoimmune disease with a complex genetic inheritance. Genome-wide association studies (GWAS) have significantly increased the number of significant loci associated with SLE risk. To date, however, established loci account for less than 30% of the disease heritability and additional risk variants have yet to be identified. Here we performed a GWAS followed by a meta-analysis to identify new genome-wide significant loci for SLE. We genotyped a cohort of 907 patients with SLE (cases) and 1524 healthy controls from Spain and performed imputation using the 1000 Genomes reference data. We tested for association using logistic regression with correction for the principal components of variation. Meta-analysis of the association results was subsequently performed on 7,110,321 variants using genetic data from a large cohort of 4036 patients with SLE and 6959 controls of Northern European ancestry. Genetic association was also tested at the pathway level after removing the effect of known risk loci using PASCAL software. We identified five new loci associated with SLE at the genome-wide level of significance (p < 5 × 10− 8): GRB2, SMYD3, ST8SIA4, LAT2 and ARHGAP27. Pathway analysis revealed several biological processes significantly associated with SLE risk: B cell receptor signaling (p = 5.28 × 10− 6), CTLA4 co-stimulation during T cell activation (p = 3.06 × 10− 5), interleukin-4 signaling (p = 3.97 × 10− 5) and cell surface interactions at the vascular wall (p = 4.63 × 10− 5). Our results identify five novel loci for SLE susceptibility, and biologic pathways associated via multiple low-effect-size loci.

1 August 2018 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Open access
CFCarlos Fernández-Díaz
Carlos Fernández-Díaz
JLJavier Loricera
Javier Loricera
Santos CastañedaSantos Castañeda
Santos Castañeda
RLRaquel López-Mejías
Raquel López-Mejías
COClara Ojeda-García
Clara Ojeda-García
RBRicardo Blanco
Ricardo Blanco
Interstitial lung disease (ILD) is one of the most serious complications of rheumatoid arthritis (RA). In the present study, we aimed to assess the efficacy of abatacept (ABA) in patients with ILD associated to RA. National multicenter, non-controlled, open-label registry study of RA patients with ILD treated with ABA. 63 patients (36 women) with RA-associated ILD undergoing ABA therapy were studied. The mean ± standard deviation age at the time of the study was 63.2 ± 9.8 years. The median duration of RA and ILD from diagnosis were 6.8 and 1 year, respectively. RA was seropositive in 55 patients (87.3%). In 15 (23.8%) of 63 patients the development of ILD was closely related to the administration of synthetic or biologic disease modifying anti-rheumatic drugs. After a follow-up of 9.4 ± 3.2 months, two-thirds of patients remained stable whereas one-quarter experienced improvement in the Modified Medical Research Council scale. At that time forced vital capacity remained stable in almost two-thirds of patents and improved in one out of five patients assessed. Also, diffusing capacity of the lung for carbon monoxide remained stable in almost two-thirds and showed improvement in a quarter of the patients assessed. At 12 months, 50% of the 22 patients in whom chest HRCT scan was performed due persistence of respiratory symptoms showed stabilization, 8 (36.4%) improvement and 3 worsening of the HRCT scan pattern. Eleven of 63 patients had to discontinue ABA, mainly due to adverse events. ABA appears to be an effective in RA-associated ILD.

1 June 2015 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
JLJavier Loricera
Javier Loricera
RBRicardo Blanco
Ricardo Blanco
José Luis HernándezJosé Luis Hernández
José Luis Hernández
Santos CastañedaSantos Castañeda
Santos Castañeda
AMAntonio Mera
Antonio Mera
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay

1 March 2016 in Medicine
Verified
Journal Article
Open access
MGMaría Galindo-Izquierdo
María Galindo-Izquierdo
EREsther Rodriguez-Almaraz
Esther Rodriguez-Almaraz
JPJosé M. Pego-Reigosa
José M. Pego-Reigosa
FLFrancisco J. López-Longo
Francisco J. López-Longo
JCJaime Calvo-Alén
Jaime Calvo-Alén
IRIñigo Rúa-Figueroa
Iñigo Rúa-Figueroa
The aim of the study was to profile those patients included in the RELESSER registry with histologically proven renal involvement in order to better understand the current state of lupus nephritis (LN) in Spain. RELESSER-TRANS is a multicenter cross-sectional registry with an analytical component. Information was collected from the medical records of patients with systemic lupus erythematosus who were followed at participating rheumatology units. A total of 359 variables including demographic data, clinical manifestations, disease activity, severity, comorbidities, LN outcome, treatments, and mortality were recorded. Only patients with a histological confirmation of LN were included. We performed a descriptive analysis, chi-square or Student's t tests according to the type of variable and its relationship with LN. Odds ratio and confidence intervals were calculated by using simple logistic regression. LN was histologically confirmed in 1092/3575 patients (30.5%). Most patients were female (85.7%), Caucasian (90.2%), and the mean age at LN diagnosis was 28.4 ± 12.7 years. The risk for LN development was higher in men (M/F:47.85/30.91%, P < 0.001), in younger individuals (P < 0.001), and in Hispanics (P = 0.03). Complete response to treatment was achieved in 68.3% of patients; 10.35% developed ESRD, which required a kidney transplant in 45% of such cases. The older the patient, the greater was the likelihood of complete response (P < 0.001). Recurrences were associated with persistent lupus activity at the time of the last visit (P < 0.001) and with ESRD (P < 0.001). Thrombotic microangiopathy was a risk factor for ESRD (P = 0.04), as for the necessity of dialysis (P = 0.01) or renal transplantation (P = 0.03). LN itself was a poor prognostic risk factor of mortality (OR 2.4 [1.81-3.22], P < 0.001). Patients receiving antimalarials had a significantly lower risk of developing LN (P < 0.001) and ESRD (P < 0.001), and responded better to specific treatments for LN (P = 0.014). More than two-thirds of the patients with LN from a wide European cohort achieved a complete response to treatment. The presence of positive anti-Sm antibodies was associated with a higher frequency of LN and a decreased rate of complete response to treatment. The use of antimalarials reduced both the risk of developing renal disease and its severity, and contributed to attaining a complete renal response.

8 January 2016 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
Mariano AndrésMariano Andrés
Mariano Andrés
MQMaría‐Amparo Quintanilla
María‐Amparo Quintanilla
FSFrancisca Sivera
Francisca Sivera
JSJosé Sánchez‐Payá
José Sánchez‐Payá
EPEliseo Pascual
Eliseo Pascual
JRJuan‐Miguel Ruiz‐Nodar
Juan‐Miguel Ruiz‐Nodar
Objective: To evaluate the association between monosodium urate (MSU) crystal deposits in patients with asymptomatic hyperuricemia and the severity and extension of coronary artery disease (CAD).Methods: In this cross‐sectional study, consecutive inpatients with a non–ST elevation acute coronary event and asymptomatic hyperuricemia (serum uric acid concentration of ≥7.0 mg/dl) or normouricemia (serum uric acid concentration of <7.0 mg/dl) were enrolled. In patients with asymptomatic hyperuricemia, the presence of MSU crystals was determined by ultrasound evaluation of both knees and first metatarsophalangeal joints and by compensated polarized light microscopy. CAD was assessed by coronary angiography, and the following variables were considered: 1) the presence of moderate‐to‐severe coronary artery calcification, 2) the number of significant coronary stenoses, and 3) the presence of multivessel disease. The association between variables indicating the severity of CAD and the presence of MSU crystals was analyzed by multivariate regression.Results: One hundred forty patients were enrolled. After ultrasonography and microscopic analyses were performed, the patients were classified as having normouricemia (n = 66), asymptomatic hyperuricemia alone (n = 61), and asymptomatic hyperuricemia with MSU crystals (n = 13). The prevalence of moderate‐to‐severe coronary calcification was significantly higher in the patients with asymptomatic hyperuricemia with MSU crystals compared with patients with asymptomatic hyperuricemia alone and patients with normouricemia (P = 0.003). An independent association was observed between the presence of moderate‐to‐severe calcification and asymptomatic hyperuricemia with crystals (odds ratio 16.8, P = 0.002). No significant association was observed for the other variables.Conclusion: Silent deposition of MSU crystals in patients with asymptomatic hyperuricemia was associated with more severe coronary calcification, which suggests more severe CAD in relation to crystal deposition.